HC Wainwright Has Bullish Estimate for EWTX FY2026 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Edgewise Therapeutics in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will earn $9.29 per share for the year, up from their prior estimate of ($2.07). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is $6.92 per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q4 2026 earnings at ($0.47) EPS and FY2027 earnings at ($2.22) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $10.18.

Several other research analysts also recently commented on EWTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. Evercore reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Edgewise Therapeutics in a research note on Monday, July 20th. William Blair started coverage on shares of Edgewise Therapeutics in a report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. lifted their target price on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $52.83.

Edgewise Therapeutics Price Performance

Shares of EWTX opened at $46.53 on Monday. Edgewise Therapeutics has a 1 year low of $18.10 and a 1 year high of $48.78. The stock has a 50 day simple moving average of $41.07 and a two-hundred day simple moving average of $36.72. The firm has a market cap of $5.09 billion, a P/E ratio of 5.68 and a beta of 0.39.

Institutional Trading of Edgewise Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its position in Edgewise Therapeutics by 64.9% during the 1st quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock valued at $33,000 after purchasing an additional 406 shares during the period. KBC Group NV purchased a new stake in shares of Edgewise Therapeutics in the 1st quarter worth about $49,000. Sterling Capital Management LLC lifted its position in shares of Edgewise Therapeutics by 840.2% in the 3rd quarter. Sterling Capital Management LLC now owns 2,360 shares of the company’s stock worth $96,000 after purchasing an additional 2,109 shares during the period. GAMMA Investing LLC lifted its position in shares of Edgewise Therapeutics by 26.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,666 shares of the company’s stock worth $108,000 after purchasing an additional 559 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Edgewise Therapeutics in the 3rd quarter worth about $225,000.

Insider Buying and Selling

In other news, CFO Michael Nofi sold 4,442 shares of Edgewise Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $45.43, for a total value of $201,800.06. Following the sale, the chief financial officer directly owned 6,495 shares in the company, valued at approximately $295,067.85. This trade represents a 40.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Joanne M. Donovan sold 2,919 shares of Edgewise Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $43.41, for a total value of $126,713.79. Following the completion of the sale, the chief marketing officer owned 8,625 shares in the company, valued at approximately $374,411.25. This represents a 25.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.